Analysis & Comment

AstraZeneca to transfer some respiratory drug rights to Covis Pharma

FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski

(Reuters) – AstraZeneca said on Monday it would transfer its global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.

Covis Pharma is expected to pay $270 million on completion of the deal and will cover certain ongoing development costs related to the medicines, London-listed AstraZeneca said.

Source: Read Full Article